Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BCAL Diagnostics Limited ( (AU:BDX) ) just unveiled an announcement.
BCAL Diagnostics Limited has entered an exclusive agreement with ClearNote Health to distribute advanced blood tests for pancreatic and ovarian cancer in Australia and New Zealand. This strategic partnership enhances BCAL’s position in the cancer detection market by expanding its portfolio beyond breast cancer tests, potentially saving lives through early detection of high-mortality cancers.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited is a company focused on oncology diagnostics, aiming to become a leader in blood-based cancer screening. It leverages partnerships with global pathology and diagnostic services to distribute its products.
Average Trading Volume: 151,556
Technical Sentiment Signal: Hold
Current Market Cap: A$24.15M
See more insights into BDX stock on TipRanks’ Stock Analysis page.